Abivax gets clearance in Spain for second phase IIa trial in HIV/AIDS patients

Abivax obtains regulatory and ethics clearance in Spain to begin second phase iia clinical trial for ABX464 in HIV/AIDS patients

* Initial results expected in Q4 2016

* Study to assess effect of ABX464 on viral load reduction after conclusion of treatment in patients controlled by Darunavir/Ritonavir

* Phase IIa clinical study will be conducted in France, Belgium and Spain

Read article here

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here